Adaptive servo-ventilation (ASV) therapy increases mortality and should not be used to treat central sleep apnea in heart failure patients with reduced ejection fraction, the SERVE-HF trial shows.
http://www.sciencedaily.com/releases/2015/09/150901115227.htm
Central sleep apnea device increases mortality in heart failure
1 September 2015
Return